A circular RNA protects the heart from pathological hypertrophy and heart failure by targeting miR-223

被引:779
|
作者
Wang, Kun [1 ]
Long, Bo [2 ,3 ]
Liu, Fang [4 ]
Wang, Jian-Xun [1 ]
Liu, Cui-Yun [1 ]
Zhao, Bing [1 ]
Zhou, Lu-Yu [1 ]
Sun, Teng [1 ]
Wang, Man [1 ]
Yu, Tao [1 ]
Gong, Ying [1 ]
Liu, Jia [1 ]
Dong, Yan-Han [1 ]
Li, Na [1 ]
Li, Pei-Feng [1 ]
机构
[1] Qingdao Univ, Inst Translat Med, Coll Med, Ctr Dev Cardiol, Qingdao 266021, Peoples R China
[2] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Cent Res Lab, Lab Mol Med, Beijing 100730, Peoples R China
[3] Peking Union Med Coll, Beijing 100730, Peoples R China
[4] Guilin Med Univ, Dept Anat, Coll Basic Med, Guilin 541004, Peoples R China
基金
北京市自然科学基金; 中国国家自然科学基金;
关键词
Circular RNA; HRCR; Cardiac hypertrophy; Heart failure; CASPASE RECRUITMENT DOMAIN; MUSCLE-SPECIFIC MICRORNA; CARDIAC-HYPERTROPHY; APOPTOSIS REPRESSOR; CARDIOMYOCYTE HYPERTROPHY; CELL PROLIFERATION; SKELETAL-MUSCLE; DIFFERENTIATION; OVEREXPRESSION; TRANSCRIPTS;
D O I
10.1093/eurheartj/ehv713
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Our present study reveals a novel cardiac hypertrophic regulating model that is composed of circRNA, miR-223, and ARC. Modulation of their levels may provide a new approach for tackling cardiac hypertrophy and heart failure. Our present work advances our understanding about the role of circRNAs and miRNAs in cardiac hypertrophy and heart failure. Circular RNA may represent a potential new therapeutic strategy to attenuate the pathogenesis of cardiac diseases.Sustained cardiac hypertrophy accompanied by maladaptive cardiac remodelling represents an early event in the clinical course leading to heart failure. Maladaptive hypertrophy is considered to be a therapeutic target for heart failure. However, the molecular mechanisms that regulate cardiac hypertrophy are largely unknown. Here we show that a circular RNA (circRNA), which we term heart-related circRNA (HRCR), acts as an endogenous miR-223 sponge to inhibit cardiac hypertrophy and heart failure. miR-223 transgenic mice developed cardiac hypertrophy and heart failure, whereas miR-223-deficient mice were protected from hypertrophic stimuli, indicating that miR-223 acts as a positive regulator of cardiac hypertrophy. We identified ARC as a miR-223 downstream target to mediate the function of miR-223 in cardiac hypertrophy. Apoptosis repressor with CARD domain transgenic mice showed reduced hypertrophic responses. Further, we found that a circRNA HRCR functions as an endogenous miR-223 sponge to sequester and inhibit miR-223 activity, which resulted in the increase of ARC expression. Heart-related circRNA directly bound to miR-223 in cytoplasm and enforced expression of HRCR in cardiomyocytes and in mice both exhibited attenuated hypertrophic responses. These findings disclose a novel regulatory pathway that is composed of HRCR, miR-223, and ARC. Modulation of their levels provides an attractive therapeutic target for the treatment of cardiac hypertrophy and heart failure.
引用
收藏
页码:2602 / U24
页数:11
相关论文
共 50 条
  • [41] Vegetable and fruit intake protects from chronic heart failure
    Kurt, Omer
    Cakar, Mustafa
    Balta, Sevket
    Sarlak, Hakan
    Akhan, Muharrem
    Demirbas, Seref
    Demirkol, Sait
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 168 (03) : 2985 - 2985
  • [42] Syndecan-4 deficiency accelerates the transition from compensated hypertrophy to heart failure following pressure overload
    Li, Guannan
    Xie, Jun
    Chen, Jianzhou
    Li, Ran
    Wu, Han
    Zhang, Xinlin
    Chen, Qinhua
    Gu, Rong
    Xu, Biao
    CARDIOVASCULAR PATHOLOGY, 2017, 28 : 74 - 79
  • [43] Bone morphogenetic protein-4: a novel therapeutic target for pathological cardiac hypertrophy/heart failure
    Guo, Wen-Ting
    Dong, De-Li
    HEART FAILURE REVIEWS, 2014, 19 (06) : 781 - 788
  • [44] Bone morphogenetic protein-4: a novel therapeutic target for pathological cardiac hypertrophy/heart failure
    Wen-Ting Guo
    De-Li Dong
    Heart Failure Reviews, 2014, 19 : 781 - 788
  • [45] Contribution of Amino Acid Transporter SLC7A5 to Pathological Ventricular Hypertrophy and Heart Failure
    Inserte, Javier
    Delgado, Sara
    Aluja, David
    Miro, Elisabet
    Ferreira, Ignacio
    Barrabes, Jose A.
    CIRCULATION, 2023, 148
  • [46] REGULATION OF THE STRUCTURAL REMODELING OF THE MYOCARDIUM - FROM HYPERTROPHY TO HEART-FAILURE
    BRILLA, CG
    MAISCH, B
    EUROPEAN HEART JOURNAL, 1994, 15 : 45 - 52
  • [47] Cardiac calcineurin during transition from hypertrophy to heart failure in rats
    Hayashida, W
    Kihara, Y
    Yasaka, A
    Sasayama, S
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 273 (01) : 347 - 351
  • [48] Cardiac ISL1-Interacting Protein, a Cardioprotective Factor, Inhibits the Transition From Cardiac Hypertrophy to Heart Failure
    Yan, Youchen
    Long, Tianxin
    Su, Qiao
    Wang, Yi
    Chen, Ken
    Yang, Tiqun
    Zhao, Guangyin
    Ma, Qing
    Hu, Xiaoyun
    Liu, Chen
    Liao, Xinxue
    Min, Wang
    Li, Shujuan
    Zhang, Dihua
    Yang, Yuedong
    Pu, William T.
    Dong, Yugang
    Wang, Da-Zhi
    Chen, Yili
    Huang, Zhan-Peng
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [49] Double- Stranded RNA- Dependent Protein Kinase Deficiency Protects the Heart From Systolic Overload- Induced Congestive Heart Failure
    Wang, Huan
    Xu, Xin
    Fassett, John
    Kwak, Dongmin
    Liu, Xiaoyu
    Hu, Xinli
    Falls, Therasa J.
    Bell, John C.
    Li, Hongliang
    Bitterman, Peter
    Bache, Robert J.
    Chen, Yingjie
    CIRCULATION, 2014, 129 (13) : 1397 - 1406
  • [50] Loss of Small Ubiquitin- Like Modifier 1 Protects the Heart From Pressure Overload-Induced Cardiac Hypertrophy and Dysfunction in Mice
    Zheng, Liuying
    Sheng, Huaxin
    Du, Xinping
    Zuo, Guoxing
    Wang, Kuan
    Paschen, Wulf
    Yang, Wei
    CIRCULATION, 2016, 134